Status:
COMPLETED
Plegridy Observational Program
Lead Sponsor:
Biogen
Conditions:
Relapsing Forms of Multiple Sclerosis
Eligibility:
All Genders
18+ years
Brief Summary
The primary objectives of the study are to determine the incidence of serious adverse events (SAEs) in participants with relapsing forms of multiple sclerosis (MS) in routine clinical practice and to ...
Eligibility Criteria
Inclusion
- Key
- Patient with MS who is newly, or is currently, prescribed Plegridy according to local label including patients who participated in Study 105MS302 (NCT01332019) or Study 105MS303 (NCT01939002).
- Patient willing and able to complete patient-reported outcomes (PRO) with minimal assistance.
- Key
Exclusion
- Concurrent enrollment in any clinical trial of an investigational product. Participation in non-interventional study can be allowed as long as this participation does not interfere with this protocol or is likely to affect the subject's ability to comply with the protocol.
- NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Key Trial Info
Start Date :
November 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 20 2022
Estimated Enrollment :
1208 Patients enrolled
Trial Details
Trial ID
NCT02230969
Start Date
November 12 2014
End Date
January 20 2022
Last Update
September 26 2022
Active Locations (152)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Homewood, Alabama, United States, 35209
2
Research Site
Gilbert, Arizona, United States, 85234
3
Research Site
Scottsdale, Arizona, United States, 85258
4
Research Site
Berkeley, California, United States, 94705